Acquired hemophilia strikes without warning and is challenging to diagnose. Delays in diagnosis and treatment put patients with acquired hemophilia at risk.3,4
Acquired hemophilia.
NovoSeven® RT is the only bypassing agent FDA-approved for acquired hemophilia,1 a spontaneous, rare, and potentially fatal disease.
Acquired hemophilia.
NovoSeven® RT is the only bypassing agent FDA-approved for acquired hemophilia,1 a spontaneous, rare, and potentially fatal disease.
Up to 21% mortality rate.2
Control the bleed with NovoSeven® RT.
An international consensus recommends NovoSeven® RT as a first-line treatment for acquired hemophilia.5
aData were extracted from a review of experiences with rFVIIa for the treatment of acquired hemophilia in compassionate-use programs, the Hemophilia & Thrombosis Research Society (HTRS) registry, the European Acquired Hemophilia (EACH2) registry, and independent published reports. Efficacy was defined as “effective” and “partially effective” treatment outcomes. “Ineffective” treatment was determined by the inability to stop the bleeding episode or by the physician describing treatment as not effective.6,7
Efficacy with NovoSeven® RT treatment.6,7,a
aData were extracted from a review of experiences with rFVIIa for the treatment of acquired hemophilia in compassionate-use programs, the Hemophilia & Thrombosis Research Society (HTRS) registry, and independent published reports. Efficacy was defined as “effective” and “partially effective” treatment outcomes. “Ineffective” treatment was determined by the inability to stop the bleeding episode or by the physician describing treatment as not effective.6,7
NovoSeven® RT is designed for safety.
NovoSeven® RT works at the site of vascular injury. It’s the only recombinant bypassing agent not made from human serum or human proteins, with 4% of patients with acquired hemophilia experiencing thrombotic events.1
Adjustable dosing.
Based on the severity of bleeding, adjust dose and frequency of injections to each individual patient.
bThe minimum effective dose has not been determined.
Dosing recommendation for acquired hemophilia.1,b
ACQUIRED HEMOPHILIA
70-90 mcg/kg
every 2-3 hours
until hemostasis is achieved
bThe minimum effective dose has not been determined.
Compare NovoSeven® RT with Obizur™ for acquired hemophilia.
Based on the initial dose for a 70-kg patient with acute bleeding
NovoSeven® RT1
Obizur™8
Approved for surgical use and
procedures in patients with
acquired hemophilia.
Looking for codes for
coagulation disorders?
